The ICF syndrome (i̲mmunodeficiency, c̲entromeric region instability, f̲acial anomalies) is a unique DNA methylation deficiency disease diagnosed by an extraordinary collection of chromosomal anomalies specifically in the vicinity of the centromeres of chromosomes 1 and 16 (Chr1 and Chr16) in mitogen-stimulated lymphocytes. These aberrations include decondensation of centromere-adjacent (qh) heterochromatin, multiradial chromosomes with up to 12 arms, and whole-arm deletions. We demonstrate that lymphoblastoid cell lines from two ICF patients exhibit these Chr1 and Chr16 anomalies in 61% of the cells and continuously generate 1qh or 16qh breaks. No other consistent chromosomal abnormality was seen except for various telomeric associations, which had not been previously noted in ICF cells. Surprisingly, multiradials composed of arms of both Chr1 and Chr16 were favored over homologous associations and cells containing multiradials with 3 or >4 arms almost always displayed losses or gains of Chr1 or Chr16 arms from the metaphase. Our results suggest that decondensation of 1qh and 16qh often leads to unresolved Holliday junctions, chromosome breakage, arm missegregation, and the formation of multiradials that may yield more stable chromosomal abnormalities, such as translocations. These cell lines maintained the abnormal hypomethylation in 1qh and 16qh seen in ICF tissues. The ICF-specific hypomethylation occurs in only a small percentage of the genome, e.g., ICF brain DNA had 7% less 5-methylcytosine than normal brain DNA. The ICF lymphoblastoid cell lines, therefore, retain not only the ICF-specific pattern of chromosome rearrangements, but also of targeted DNA hypomethylation. This hypomethylation of heterochromatic DNA sequences is seen in many cancers and may predispose to chromosome rearrangements in cancer as well as in ICF.   

1.
Almeida A, Kokalj-Vokac N, Lefrancois D, Viegas-Péquignot E, Jeanpierre M, Dutrillaux B, Malfoy B: Hypomethylation of classical satellite DNA and chromosome instability in lymphoblastoid cell lines. Hum Genet 91:538–546 (1993).
2.
Brown DC, Grace E, Summer AT, Edmunds AT, Ellis PM: ICF syndrome (immunodeficiency, centromeric instability and facial anomalies): investigation of heterochromatin abnormalities and review of clinical outcome. Hum Genet 96:411–416 (1995).
3.
Carpenter NJ, Fillpovich A, Blaese RM, Carey TL, Berkel AI: Variable immunodeficiency with abnormal condensation of the heterochromatin of chromosomes 1, 9, and 16. J Ped 112:757–760 (1988).
4.
Ehrlich M, Gama-Sosa M, Huang L-H, Midgett RM, Kuo KC, McCune RA, Gehrke C: Amount and distribution of 5-methylcytosine in human DNA from different types of tissues or cells. Nucl Acids Res 10:2709–2721 (1982).
5.
Fasth A, Forestier E, Holmberg E, Holmgren G, Nordenson I, Soderstrom T, Wahlstrom J: Fragility of the centromeric region of chromosome 1 associated with combined immunodeficiency in siblings: a recessively inherited entity? Acta Paediatr Scand 79:605–612 (1990).
6.
Fryns JP, Azou M, Jacken J, Eggermont E, Pedersen JC, Van den Berghe H: Centromeric instability of chromosomes 1, 9, and 16 associated with combined immunodeficiency. Hum Genet 57:108–110 (1981).
7.
Gama-Sosa MA, Slagel VA, Trewyn RW, Oxenhandler R, Kuo KC, Gehrke CW, Ehrlich M: The 5-methylcytosine content of DNA from human tumors. Nucl Acids Res 11:6883–6894 (1983a).
8.
Gama-Sosa MA, Wang RY-H, Kuo KC, Gehrke CW, Ehrlich M: The 5-methylcytosine content of highly repeated sequences in human DNA. Nucl Acids Res 11:3087–3095 (1983b).
9.
Haaf T: The effects of 5-azacytidine and 5-azadeoxycytidine on chromosome structure and function: implications for methylation-associated cellular processes. Pharmac Ther 65:19–46 (1995).
10.
Haaf T, Schmid M: Chromosome topology in mammalian interphase nuclei. Exp Cell Res 192:325–332 (1991).
11.
Haber JE: Sir-Ku-itous routes to make ends meet. Cell 97:829–832 (1999).
12.
Heim S, Mitelman F: Cancer Cytogenetics (Wiley-Liss, New York 1995).
13.
Hernandez R, Frady A, Zhang X-Y, Varela M, Ehrlich M: Preferential induction of chromosome 1 multibranched figures and whole-arm deletions in a human pro-B cell line treated with 5-azacytidine or 5-azadeoxycytidine. Cytogenet Cell Genet 76:196–201 (1997).
14.
Hulten M: Selective somatic pairing and fragility at 1q12 in a boy with common variable immunodeficiency. Clin Genet 14:294 (1978).
15.
Jannink G, Duplantier B, Sikorav JL: Forces on chromosomal DNA during anaphase. Biophys J 71:451–465 (1996).
16.
Jeanpierre M: Human satellite 2 and 3. A Rev Genet 37:163–171 (1994).
17.
Jeanpierre M, Turleau C, Aurias A, Prieur M, Ledeist F, Fischer A, Viegas-Péquignot E: An embryonic-like methylation pattern of classical satellite DNA is observed in ICF syndrome. Hum Molec Genet 2:731–735 (1993).
18.
Ji W, Hernandez R, Zhang X-Y, Qu G, Frady A, Varela M, Ehrlich M: DNA demethylation and pericentromeric rearrangements of chromosome 1. Mutation Res 379:33–41 (1997).
19.
Kondo T, Comenge Y, Bobek MP, Kuick R, Lamb B, Zhu X, Narayan A, Bourc’his D, Viegas-Péquinot E, Ehrlich M, Hanash S: Whole-genome methylation scan in ICF syndrome: hypomethylation of non-satellite DNA repeats D4Z4 and NBL2. Hum Mol Gen: in press (2000).
20.
Kuo KC, McCune RA, Gehrke CW, Midgett R, Ehrlich M: Quantitative reversed-phase high performance liquid chromatographic determination of major and modified deoxyribonucleosides in DNA. Nucl Acids Res 8:4763–4776 (1980).
21.
Lukacsovich T, Waldman AS: Suppression of intrachromosomal gene conversion in mammalian cells by small degrees of sequence divergence. Genetics 151:1559–1568 (1999).
22.
Maraschio P, Cortinovis M, Dainotti E, Tupler R, Tiepolo L: Interphase cytogenetics of the ICF syndrome. Ann hum Genet 56:273–278 (1992).
23.
Mertens F, Johansson B, Hoglund M, Mitelman F: Chromosomal imbalance maps of malignant solid tumors: a cytogenetic survey of 3185 neoplasms. Cancer Res 57:2765–2780 (1997).
24.
Miniou P, Jeanpierre M, Bourc’his D, Coutinho Barbosa AC, Blanquet V, Viegas-Péquignot E: Alpha-satellite DNA methylation in normal individuals and in ICF patients: heterogeneous methylation of constitutive heterochromatin in adult and fetal tissues. Hum Genet 99:738–745 (1997).
25.
Moyzis RK, Albright KL, Bartholdi MF, Cram LS, Deaven LL, Hildebrand CE, Joste NE, Longmire JL, Meyne J, Schwarzacher-Robinson T: Human chromosome-specific repetitive DNA sequences: novel markers for genetic analysis. Chromosoma 95:375–386 (1987).
26.
Narayan A, Ji W, Zhang X-Y, Marrogi A, Graff JR, Baylin SB, Ehrlich M: Hypomethylation of pericentromeric DNA in breast adenocarcinomas. Int J Cancer 77:833–838 (1998).
27.
Okano M, Bell DW, Haber DA, Li E: DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 98:247–257 (1999).
28.
Qu G, Dubeau L, Narayan A, Yu M, Ehrlich M: Satellite DNA hypomethylation vs. overall genomic hypomethylation in ovarian epithelial tumors of different malignant potential. Mut Res 423:91–101 (1999a).
29.
Qu G, Grundy PE, Narayan A, Ehrlich M: Frequent hypomethylation in Wilms tumors of pericentromeric DNA in chromosomes 1 and 16. Cancer Genet Cytogenet 109:34–39 (1999b).
30.
Sawyer J, Tricot G, Mattox S, Jagannath S, Barlogie B: Jumping translocations of chromosome 1q in multiple myeloma: evidence for a mechanism involving decondensation of pericentromeric heterochromatin. Blood 91:1732–1741 (1998).
31.
Sawyer JR, Swanson CM, Wheeler G, Cunniff C: Chromosome instability in ICF syndrome: formation of micronuclei from multibranched chromosome 1 demonstrated by fluorescence in situ hybridization. Am J med Genet 56:203–209 (1995).
32.
Smeets DFCM, Moog U, Weemaes CMR, Vaes-Peeters G, Merkx GFM, Niehof JP, Hamers G: ICF syndrome: a new case and review of the literature. Hum Genet 94:240–246 (1994).
33.
Smilenov LB, Morgan SE, Mellado W, Sawant SG, Kastan MB, Pandita TK: Influence of ATM function on telomere metabolism. Oncogene 15:2659–2665 (1997).
34.
Sumner AT, Mitchell AR, Ellis PM: A FISH study of chromosome fusion in the ICF syndrome: involvement of paracentric heterochromatin but not of the centromeres themselves. J Med Genet 35:833–835 (1998).
35.
Tiepolo L, Maraschio P, Gimelli G, Cuoco C, Gargani GF, Romano C: Multibranched chromosomes 1, 9, and 16 in a patient with combined IgA and IgE deficiency. Hum Genet 51:127–137 (1979).
36.
Thoraval D, Asakawa J, Kodaira M, Chang C, Radany E, Kuick R, Lamb B, Richardson B, Neel JV, Glover T, Hanash S: A methylated human 9-kb repetitive sequence on acrocentric chromosomes is homologous to a subtelomeric repeat in chimpanzees. Proc natl Acad Sci, USA 93:4442–4447 (1996).
37.
Tommerup N: Triradial configurations indicate that expression of the fragile site at Xq27 is non-lethal. Ann Genet 30:231–232 (1987).
38.
Turleau C, Cabanis M-O, Girault D, Ledeist F, Mettey R, Puissant H, Marguerite P, de Grouchy J: Multibranched chromosomes in the ICF syndrome: Immunodeficiency, centromeric instability, and facial anomalies. Am J med Genet 32:420–424 (1989).
39.
Waye JS, Durfy SJ, Pinkel D, Kenwrick S, Patterson M, Davies KE, Willard HF: Chromosome-specific alpha satellite DNA from human chromosome 1: hierarchical structure and genomic organization of polymorphic domain spanning several hundred kilobase pairs of centromeric DNA. Genomics 1:43–51 (1987).
40.
Xu G, Bestor TH, Bourc’his D, Hsieh C, Tommerup N, Hulten M, Qu S, Russo JJ, Viegas-Péquignot E: Chromosome instability and immunodeficiency syndrome caused by mutations in a DNA methyltransferase gene. Nature 401:187–191 (1999).
41.
Zahrt TC, Maloy S: Barriers to recombination between closely related bacteria: MutS and RecBCD inhibit recombination between Salmonella typhimurium and Salmonella typhi. Proc natl Acad Sci, USA 94:9786–9791 (1997).
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.